Late effects surveillance system for sarcoma patients.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity; D004317:Doxorubicin / Q000008:administration & dosage / Q000633:toxicity; D005240:Feasibility Studies; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000633:toxicity; D007223:Infant; D007674:Kidney Diseases / Q000139:chemically induced; D008274:Magnesium / Q000378:metabolism; D010710:Phosphates / Q000378:metabolism; D010865:Pilot Projects; D011159:Population Surveillance; D012509:Sarcoma / Q000150:complications* / Q000188:drug therapy*; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced
D000970:Antineoplastic Agents; D010710:Phosphates; D004317:Doxorubicin; D008274:Magnesium; D002945:Cisplatin; D007069:Ifosfamide